Repatha Does Not Need to Be Held Prior to Surgery
Repatha (evolocumab) does not require discontinuation before surgery. This PCSK9 inhibitor is a lipid-lowering agent, not an anticoagulant or antiplatelet medication, and therefore does not increase bleeding risk during surgical procedures.
Mechanism and Perioperative Safety
Evolocumab works by inhibiting PCSK9 enzyme, which increases LDL receptor availability and lowers LDL cholesterol levels 1. Unlike anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel) that directly affect hemostasis, Repatha has no impact on coagulation pathways or platelet function 1.
The available perioperative guidelines address management of:
- Vitamin K antagonists (warfarin): stop 5 days before surgery 2
- Direct oral anticoagulants: stop 3-5 days before major surgery depending on agent 3
- Antiplatelet drugs: aspirin continued or stopped 5-7 days; clopidogrel stopped 5-7 days before surgery 2, 3, 4
Notably absent from all perioperative antithrombotic guidelines is any mention of PCSK9 inhibitors, because they do not affect bleeding risk 2, 3, 2, 3, 4.
Clinical Considerations
Continue Repatha Perioperatively
- No interruption needed for any type of surgery (minor or major)
- No bridging therapy required (unlike high-risk patients on anticoagulation)
- The drug can be administered on its regular schedule (every 2 weeks or monthly) regardless of surgical timing 1
Cardiovascular Protection
Continuing Repatha perioperatively may actually be beneficial in high-risk cardiovascular patients:
- Statins are recommended to continue perioperatively for cardiovascular protection 5
- Evolocumab provides additional LDL-C lowering beyond statins 6
- Research suggests perioperative use may be safe and potentially beneficial in MI patients 7
Practical Management
The only perioperative consideration for Repatha relates to latex sensitivity: some presentations contain dry natural rubber in the needle cover, which may cause allergic reactions in latex-sensitive individuals 1. In such cases, prescribe the latex-free presentation (on-body infusor with prefilled cartridge) 1.
Common Pitfall to Avoid
Do not confuse lipid-lowering agents with antithrombotic medications. The extensive perioperative guidelines for managing anticoagulants and antiplatelet drugs 2, 3, 2, 3, 4 do not apply to PCSK9 inhibitors like Repatha. There is no pharmacologic rationale for discontinuation, and doing so unnecessarily interrupts important cardiovascular risk reduction therapy.